Rollins Trades Near 50 Times Earnings on 6.6% Organic Growth as Bought Deals Pad the Topline

---

Begin with the quality, because Rollins's excellence is the foundation of the bull case and deserves to be stated plainly before any skepticism begins. The company owns Orkin, the most recognized name in American pest control, along with a sprawling family of regional brands, and it sells a service that most customers treat as non-negotiable: a recurring contract to keep their homes and businesses free of the pests that no one will tolerate. Revenue is overwhelmingly recurring, churn is low, the business throws off cash, and it has compounded through recessions, housing downturns, and the pandemic without a meaningful interruption. In the first quarter of 2026, reported on April 23, Rollins grew revenue 10.2% to $906.4 million, expanded across every service line, and reaffirmed full-year guidance built on 7% to 8% organic growth. These are the numbers of a thoroughbred, and the market's affection for them is not irrational.

The question is not whether Rollins is a great company — it manifestly is — but whether the price the market is paying leaves any room for the ordinary disappointments that befall ordinary businesses. At roughly 49 times trailing earnings and around 44 times forward earnings, Rollins carries a multiple typically reserved for asset-light, secular compounders whose growth is structurally insulated from the economy and arithmetically explosive. Rollins's organic growth, stripped of acquisitions, was 6.6% in the most recent quarter — a fine number for a mature services firm, but a strikingly modest one to underpin a software-style valuation. This essay examines the gap between that price and that reality: the bought growth now layered on top of the organic, the quality-of-earnings details inside the adjusted figures, the margins that quietly compressed, the denominator effects flattering the optics, and the asymmetry of paying fifty times for a mid-single-digit compounder.

A multiple priced for software on a business that sprays for termites

Start with what nearly 50 times earnings actually demands. A multiple like that is normally the market's way of saying it expects durable, high-teens-or-better growth for years, with margins that expand on near-zero incremental cost, and a business so insulated from the cycle that the ordinary rules of valuation no longer bind. That description fits a dominant software platform whose code costs nothing to copy. It fits Rollins only in the loosest analogical sense. Rollins runs a continent-spanning network of branches, trucks, and technicians who physically drive to homes and businesses, inspect for infestations, and apply treatments. Its growth comes from a slow, route-by-route grind of adding customers, raising prices, and bolting on regional competitors — admirable, durable work, but not the frictionless, exponential kind the multiple implies.

That is a fundamentally different animal from software, and it deserves a fundamentally different valuation framework. The forward multiple sits more than two hundred percent above the median for personal-services peers, and the PEG ratio — price-to-earnings weighed against the growth rate — runs above three, a level that tells you investors are paying a steep premium relative to how fast earnings are actually compounding. A PEG above three is the market's quiet admission that the price has run ahead of the growth. Pricing a labor-intensive, route-density services firm as though it were a secular software platform is the central tension of the Rollins story. The market has decided the quality is so high that the ordinary arithmetic of its category no longer applies — and history is unkind to that decision when it is made at a valuation peak on a business growing organically in the mid-single digits.

Bought growth is propping up the organic story

Here is the move that the headline 10.2% growth obscures. Of that total, only 6.6 percentage points came from the organic business — existing customers, new sales, and price increases. The remainder came from acquisitions: the smaller pest-control companies Rollins buys, folds into its network, and counts toward consolidated revenue. Management's own framework for the year is explicit about this split: roughly 7% to 8% organic growth, plus another 2% to 3% bolted on through mergers and acquisitions, for total growth in the 9% to 11% range. In other words, a third or more of the company's headline growth is purchased, not generated by the underlying engine. The double-digit topline that helps justify a near-50-times multiple is, in meaningful part, an artifact of the checkbook.

This matters because bought growth and organic growth are not the same quality of growth, and the market too often prices them as if they were. Organic growth is the pure signal of a business's pricing power and customer demand; it requires no fresh capital beyond ordinary reinvestment and it compounds on itself. Acquired growth, by contrast, must be paid for in cash and dilution, carries integration risk, and tends to come at the cost of goodwill that piles up on the balance sheet. A company that must continually buy smaller rivals to sustain a double-digit topline is, in effect, running on a treadmill: the moment the deal flow slows, the headline growth rate steps down toward the organic rate beneath it. At Rollins, that underlying rate is mid-to-high single digits — perfectly respectable, but nowhere near what fifty times earnings is paying for.

The serial roll-up and the cost of feeding it

Look at the cadence of acquisitions and the price of the appetite. Rollins is, structurally, a serial roll-up. In 2025 it deployed roughly $310 million on acquisitions, including the sizable Saela Pest Control deal that closed in April of that year and the earlier Fox Pest Control transaction, and it has continued the pattern into 2026 with the Romex Pest Control acquisition opening new markets and expanding its residential and ancillary footprint. Public trackers count dozens of acquisitions over the company's history. This is the engine that converts a mid-single-digit organic grower into a low-double-digit reported grower, and it is the engine the multiple is implicitly extrapolating into perpetuity.

The trouble with a roll-up priced for perfection is that it requires three things to remain true simultaneously, indefinitely: an ample supply of attractive targets, disciplined prices paid for them, and clean integration. None of those is guaranteed. The pest-control industry is consolidating, which means the field of independent operators large enough to move Rollins's needle is shrinking even as competition for them intensifies — Rollins is not the only acquirer at the table. As targets get scarcer and bidders multiply, the prices paid tend to rise and the returns on those deals tend to fall. The phrase a careful analyst should watch for is "tolerant pricing" on acquisitions: the willingness to pay up for deals because the deals are needed to keep the growth story intact. A roll-up that needs to keep buying, into a thinning and more contested market, at a valuation that assumes the buying never gets harder or pricier, is exactly the kind of structure that looks flawless until the deal math quietly stops working.

Goodwill, adjusted earnings, and the quality-of-earnings question

Follow the accounting trail that serial acquisition leaves behind. Every deal Rollins closes adds intangibles and goodwill to the balance sheet, and the adjustments that flow through earnings deserve scrutiny. Consider the gap that opened in the first quarter of 2026: GAAP earnings per share were flat at $0.22, while adjusted earnings per share rose 9.1% to $0.24. That divergence — a flat GAAP number sitting beneath a growing adjusted number — is precisely the kind of detail a quality-of-earnings review exists to interrogate. The bridge between the two runs through items management asks investors to look past, including adjustments tied to the fair value of contingent consideration on the Fox and Saela acquisitions. Those are real, deal-driven charges; whether they should be excluded from the "true" earnings power is a judgment call, and the market has clearly chosen the more flattering of the two figures.

This is the denominator-and-adjustment game that premium multiples invite. When a stock trades near fifty times GAAP earnings, every dollar of GAAP profit is being valued extraordinarily richly, which creates enormous incentive to steer attention toward the adjusted figure that grows faster. The skeptic's discipline is to anchor on the GAAP number — the one that was flat this quarter — and to treat the adjusted figure as a supplement rather than the truth. A business whose reported, unadjusted earnings did not grow year-over-year in a quarter where revenue rose double digits is telling you something about the cost of that revenue. The bull will say the flat GAAP EPS reflects seasonal timing and pre-peak-season investment; the skeptic will note that "look at the adjusted number" is the most reliable tell in all of equity analysis, and that fifty times earnings affords no margin for the gap to widen.

Margins compressed in the quarter the bulls call efficient

Examine the profitability beneath the growth, because this is where the defensive-compounder narrative meets some friction. In the first quarter of 2026, gross margins declined by roughly 60 basis points, which management attributed to lower volume in the early part of the quarter and to increased insurance and claims activity. Operating margin fell to 16.1%, a decline of about 120 basis points versus the prior year, and even the adjusted operating margin slipped roughly 100 basis points to 16.9%. Selling, general, and administrative spending was pressured by incremental sales and marketing investment ahead of the peak pest season. None of these is catastrophic, and seasonally soft first quarters are normal for the business. But the direction matters: a stock priced for relentless, software-like margin expansion delivered margin contraction in the very quarter it reported double-digit revenue growth.

The reason this is more than a rounding error is the labor-and-claims structure of the business. Rollins's costs are dominated by people — technicians, drivers, sales staff — and by the insurance and claims exposure that comes with sending thousands of workers into customers' homes and businesses every day. These are not costs that fall toward zero as revenue scales; they rise broadly in line with the work performed, and they are exposed to wage inflation and rising insurance costs in ways a software business is not. When insurance and claims activity ticks up, as it did this quarter, it lands directly on the gross margin. A premium multiple is, at root, a bet that margins march steadily higher; a quarter of margin compression on rising revenue is a small but real piece of evidence pointing the other way, and at this price the evidence is not free.

The denominator illusion in the price-increase story

Parse the pricing claim carefully, because it is doing quiet work in the bull case. Management says price increases are expected to add 3% to 4% to growth in 2026, outpacing the consumer price index. That sounds like durable pricing power, and to a degree it is — recurring pest-control contracts are sticky, and customers rarely cancel over a modest annual increase. But notice what it implies about the volume side of the ledger. If organic growth is running 6.6% to 8%, and 3% to 4% of that is price, then the volume component — the actual addition of new customers and new contracts — is running only in the low-to-mid single digits. The growth that looks robust in aggregate is, on closer inspection, half price and half a fairly modest unit expansion.

This is the denominator illusion that flatters mature compounders. Price increases are the easiest growth to manufacture and the first to reverse when the economy softens or a competitor undercuts; they borrow from the future by raising the bar customers must accept each year. Volume growth is the harder, truer signal of a business taking share and expanding its market. A pest-control firm leaning on price for half its organic growth, in a category where the underlying number of homes and businesses grows slowly, is a firm whose real, demand-driven expansion is more modest than the headline suggests. At fifty times earnings, the market is paying for durable, demand-led compounding; a meaningful share of what it is actually getting is annual price hikes against a slowly growing base.

Defensive does not mean cheap, and recession-resistant is not recession-proof

Confront the heart of the bull thesis directly: the idea that Rollins is so defensive, so recession-resistant, that it deserves to trade like a bond with a growth kicker. There is real truth in it — pest control is closer to a necessity than a luxury, and a homeowner battling termites will pay the bill in good times and bad. But "defensive" is a statement about the stability of the business, not about the attractiveness of the price, and the two are constantly conflated. The most dangerous moment to own a defensive compounder is precisely when the market has fallen so in love with its stability that it bids the multiple to a level where future returns are mathematically capped, no matter how steady the underlying cash flows.

And recession-resistant is not recession-proof. A chunk of Rollins's growth comes from residential and commercial demand that is at least loosely tied to housing turnover, business formation, and discretionary upgrades to ancillary services — the add-ons customers buy when they feel flush and trim when they do not. In a genuine downturn, customers downgrade service tiers, defer the optional treatments, and shop the contract; the recurring base holds, but the growth at the margin softens. The bull case treats Rollins's revenue as if it were a utility bill that only ever rises. The reality is a sturdy core wrapped in a layer of more cyclical, more discretionary growth — and it is that growth layer, not the core, that the premium multiple is paying for.

The asymmetry of paying fifty times for a single-digit compounder

Step back and weigh the trade the way a skeptic must: what is the shape of the bet at this price? When a high-quality business grows organically in the mid-to-high single digits and trades near fifty times trailing earnings, the return math turns punishing. Even flawless execution — years of steady organic growth, disciplined acquisitions, gradual margin gains — may struggle to deliver attractive returns from this starting point, because so much of the future is already capitalized into the price. The upside is the slow grind of compounding partly offset by multiple compression as growth matures. The downside is the same multiple compression accelerated by any stumble: a slowing deal pipeline, a soft season, a wage or insurance shock, a couple of quarters where GAAP earnings simply do not grow.

That asymmetry is the whole argument. A stock at fifty times earnings does not need a scandal to disappoint; it needs only to be ordinary. If the multiple drifts from the high-forties toward the high-twenties or low-thirties that a mid-single-digit compounder would more typically command — still a premium, just a saner one — the price falls meaningfully even as the business keeps performing exactly as advertised. The bull is betting the multiple holds because the quality is permanent; the skeptic is observing that the quality and the price are two different things, and that the most reliable way to lose money in a wonderful business is to pay a price that already assumes a decade of perfection. Rollins may well keep compounding. The question is whether, from here, the shareholder gets paid for it.

What the bulls genuinely get right

Concede the strength of the bull case fully and specifically, because it is real and it is the reason this stock has earned its following. Rollins's revenue is genuinely recurring and genuinely sticky: pest control is a service customers renew almost without thinking, churn is low, and the contracts roll forward through economic weather that would wreck a more cyclical firm. The first quarter of 2026 was not a weak quarter — revenue grew 10.2% to $906.4 million, every service line expanded, and residential, commercial, and termite all posted healthy gains. The cash generation is excellent: 2025 operating cash flow rose 11.6% to $678 million and free cash flow reached roughly $650 million, up double digits, which is exactly what funds both the acquisitions and a steadily growing dividend without straining the balance sheet. This is a business that turns recurring revenue into real, distributable cash with unusual reliability.

The acquisition strategy, for all the treadmill risk, has a genuine logic the bulls are right to credit. Pest control is a fragmented, local-density business where route efficiency is everything, and Rollins's national scale lets it buy small operators and immediately improve their economics by layering them onto existing routes and back-office systems. That is a real, repeatable source of value creation, not financial engineering for its own sake — and the company has executed it well for years. Pricing power is real too: customers do absorb 3% to 4% annual increases without meaningful defection, which is more than most businesses can claim. And the defensive profile is not a myth; in a market full of speculative, unprofitable growth stories, a profitable, cash-generative, recession-resistant compounder is a legitimately scarce and valuable thing. The skeptic's quarrel is with the price, not the enterprise — and an honest analysis has to say so clearly.

The kicker

So weigh it honestly. Rollins is a superb business — recurring, defensive, cash-rich, run by people who have compounded shareholder capital for decades through a patient roll-up of a fragmented industry. Strip away the affection, though, and what the most recent quarter actually shows is a company growing organically in the mid-single digits, padding its topline to double digits by writing checks for smaller rivals, watching its GAAP earnings sit flat while it points investors to the adjusted figure, and absorbing margin compression in the very quarter it called a growth quarter — all while its stock changes hands near fifty times earnings, a price built for software and paid for pest control. None of that makes Rollins a bad company; it makes it an expensive one, and those are not the same thing, though a peak market loves to pretend they are.

The danger was never that Orkin would stop killing termites; it was that investors would pay fifty times earnings for a mid-single-digit compounder and call the price a margin of safety.